semaglutide 2.5 mg/ml Flex-Dose 2 mL Injectable Semaglutide / Niacinamide – WP

While 2.4 mg is the highest commonly prescribed dose for weight management, many people achieve their weight-loss goals at lower maintenance doses like 1.0 mg or 1.7 mg

DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period

Limitations A key limitation to using Mounjaro for weight loss is that it is not currently FDA-approved to decrease weight

Headache: Pain relievers such as acetaminophen or ibuprofen may alleviate symptoms